Compare

AOD-9604 vs ARA-290

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

AOD-9604

2248 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 52% · Mixed 36% · Unfavorable overall 12%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Digestive comfort
-165
Skin appearance
-101
Appetite control
-115
Energy
-49
Mood
-86

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Flushing
-69
Headache
-21
GI discomfort
-150
Dizziness
-54
Fatigue
-87

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 10–600 mcg

10–25
3
25–50
5
50–100
14
100–200
18
200–400
9
400–600
6

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing12stacking30side effects18aod-96046

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 32% more positive, and 12% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 27 days · Based on 495 repeat reporters

ARA-290

2396 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 50% · Mixed 34% · Unfavorable overall 16%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
79
Focus
110
Sleep quality
159
Lean mass
165
Joint comfort
98

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
175
Nausea
189
Water retention
124
Appetite loss
161
Injection site reaction
98

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 25–600 mcg

25–50
8
50–100
16
100–200
19
200–400
14
400–600
8

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing40stacking13side effects16ara-29029

How repeat users are trending

Among repeat reporters, 60% said they felt similar to their last entry, 30% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 31 days · Based on 527 repeat reporters

Sources (8)

Published sources linked on the AOD-9604 and ARA-290 wiki pages.

  1. PubMed

    A synthetic fragment of human growth hormone promotes lipid mobilization

    Heffernan MA, Thorburn AW, Fam B, et al. Int J Obes Relat Metab Disord. 2001

    Source
    Wiki study page →
  2. PubMed

    A synthetic human growth hormone fragment enhances proteoglycan synthesis

    Ng FM, Sun J, Sharma L, et al. Osteoarthritis Cartilage. 2010

    Source
    Wiki study page →
  3. ClinicalTrials.gov

    AOD9604 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  4. PubMed

    Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment

    Heffernan MA, Thorburn AW, Fam B, et al. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 2001

    Source
    Wiki study page →
  5. PubMed

    The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice

    Heffernan M, Summers RJ, Thorburn A, et al. Endocrinology. 2001

    Source
    Wiki study page →
  6. PubMed

    ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves neuropathic symptoms in patients with sarcoidosis

    Dahan A, Dunne A, Swartjes M, et al. Mol Med. 2013

    Source
    Wiki study page →
  7. PubMed

    ARA 290 for treatment of small fiber neuropathy in sarcoidosis

    van Velzen M, Heij L, Niesters M, et al. Expert opinion on investigational drugs. 2014

    Source
    Wiki study page →
  8. PubMed

    The time to develop treatments for diabetic neuropathy

    Rendell MS. Expert opinion on investigational drugs. 2021

    Source
    Wiki study page →